Pacira Biosciences Inc
PCRX22.530USD
+0.340+1.53%
交易中 （美東）報價延遲15分鐘
1.01B總市值
虧損本益比TTM
關於 Pacira Biosciences Inc 公司
Pacira BioSciences, Inc. 是 Pacira Pharmaceuticals, Inc. 的控股公司。該公司的非阿片類治療藥物包括 EXPAREL（布比卡因脂質體注射混懸液），這是一種用於術後疼痛管理的長效局部鎮痛藥；ZILRETTA（曲安奈德緩釋注射混懸液），這是一種緩釋關節內 (IA) 皮質類固醇注射劑，用於治療 OA 膝關節疼痛；以及 Iovera，這是一種新型手持設備，可通過精確控制的低溫劑量向目標神經提供即時、長效、無藥物的疼痛控制。EXPAREL 用於多種骨科手術，包括關節重建、肩部、脊柱、四肢手術和髖部骨折。該公司正在開發干預措施來治療涉及交感神經系統的衰弱性疾病，例如心臟電風暴、慢性疼痛。其臨牀開發項目包括 PCRX-201 和基於 pMVL 的臨牀項目。
Pacira Biosciences Inc簡介
公司代碼PCRX
公司名稱Pacira Biosciences Inc
上市日期Feb 03, 2011
CEOMr. Frank D. Lee
員工數量790
證券類型Ordinary Share
年結日Feb 03
公司地址2000 Sierra Point Parkway
城市BRISBANE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94005
電話16502428052
網址https://www.pacira.com/
公司代碼PCRX
上市日期Feb 03, 2011
CEOMr. Frank D. Lee
Pacira Biosciences Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Mark A. Kronenfeld, M.D.
Dr. Mark A. Kronenfeld, M.D.
Independent Director
Independent Director
34.90K
+40.15%
Dr. Jonathan Slonin, M.D.
Dr. Jonathan Slonin, M.D.
Chief Medical Officer
Chief Medical Officer
34.37K
-0.91%
Mr. Daryl Gaugler
Mr. Daryl Gaugler
Executive Vice President - Commercial Operations
Executive Vice President - Commercial Operations
32.29K
-51.29%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Chairman of the Board
Independent Chairman of the Board
23.71K
+35.11%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
9.04K
-20.66%
Ms. Lauren Riker
Ms. Lauren Riker
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
5.98K
-59.94%
Mr. Michael J. Yang
Mr. Michael J. Yang
Independent Director
Independent Director
--
--
Mr. Shawn M. Cross
Mr. Shawn M. Cross
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Marcelo Bigal, M.D., Ph.D.
Dr. Marcelo Bigal, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Susan Mesco
Ms. Susan Mesco
Investor Relations
Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Mark A. Kronenfeld, M.D.
Dr. Mark A. Kronenfeld, M.D.
Independent Director
Independent Director
34.90K
+40.15%
Dr. Jonathan Slonin, M.D.
Dr. Jonathan Slonin, M.D.
Chief Medical Officer
Chief Medical Officer
34.37K
-0.91%
Mr. Daryl Gaugler
Mr. Daryl Gaugler
Executive Vice President - Commercial Operations
Executive Vice President - Commercial Operations
32.29K
-51.29%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Chairman of the Board
Independent Chairman of the Board
23.71K
+35.11%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
9.04K
-20.66%
Ms. Lauren Riker
Ms. Lauren Riker
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
5.98K
-59.94%
收入明細
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
業務USD
名稱
營收
佔比
EXPAREL
142.92M
0.00%
ZILRETTA
31.33M
0.00%
iovera
5.59M
0.00%
Bupivacaine liposome injectable suspension
508.00K
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
EXPAREL
142.92M
0.00%
ZILRETTA
31.33M
0.00%
iovera
5.59M
0.00%
Bupivacaine liposome injectable suspension
508.00K
0.00%
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
14.89%
The Vanguard Group, Inc.
11.92%
DOMA Perpetual Capital Management, LLC
6.01%
Renaissance Technologies LLC
5.33%
D. E. Shaw & Co., L.P.
5.01%
其他
56.84%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
14.89%
The Vanguard Group, Inc.
11.92%
DOMA Perpetual Capital Management, LLC
6.01%
Renaissance Technologies LLC
5.33%
D. E. Shaw & Co., L.P.
5.01%
其他
56.84%
股東類型
持股股東
佔比
Investment Advisor
51.44%
Investment Advisor/Hedge Fund
29.98%
Hedge Fund
25.77%
Research Firm
5.21%
Pension Fund
2.17%
Individual Investor
1.51%
Bank and Trust
1.03%
Holding Company
0.30%
Sovereign Wealth Fund
0.04%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
594
52.02M
115.78%
-16.12M
2025Q2
613
53.27M
118.43%
-16.03M
2025Q1
638
53.73M
116.03%
-16.46M
2024Q4
638
52.13M
112.66%
-21.91M
2024Q3
638
53.62M
116.22%
-11.06M
2024Q2
624
54.29M
116.65%
-6.10M
2024Q1
627
51.47M
110.71%
-7.99M
2023Q4
621
50.55M
108.88%
-6.71M
2023Q3
612
49.73M
107.18%
-6.05M
2023Q2
605
49.27M
107.14%
-5.45M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
6.69M
14.89%
-72.97K
-1.08%
Jun 30, 2025
The Vanguard Group, Inc.
5.36M
11.92%
+165.93K
+3.20%
Jun 30, 2025
DOMA Perpetual Capital Management, LLC
2.70M
6.01%
+894.55K
+49.59%
Aug 05, 2025
Renaissance Technologies LLC
2.40M
5.33%
--
--
Jun 30, 2025
D. E. Shaw & Co., L.P.
2.25M
5.01%
-10.54K
-0.47%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.15M
4.79%
+102.21K
+4.99%
Jun 30, 2025
Balyasny Asset Management LP
2.13M
4.74%
+565.29K
+36.11%
Jun 30, 2025
State Street Investment Management (US)
1.95M
4.34%
-28.76K
-1.45%
Jun 30, 2025
American Century Investment Management, Inc.
1.18M
2.63%
+515.09K
+77.18%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.14M
2.54%
+5.66K
+0.50%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
Invesco Pharmaceuticals ETF
2.69%
SPDR S&P Pharmaceuticals ETF
1.8%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.35%
ETC 6 Meridian Small Cap Equity ETF
1.09%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.94%
Simplify Health Care ETF
0.92%
Invesco S&P SmallCap Health Care ETF
0.74%
VictoryShares Small Cap Free Cash Flow ETF
0.7%
Royce Quant Small-Cap Quality Value ETF
0.53%
Distillate Small/Mid Cash Flow ETF
0.48%
查看更多
Invesco Pharmaceuticals ETF
佔比2.69%
SPDR S&P Pharmaceuticals ETF
佔比1.8%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比1.35%
ETC 6 Meridian Small Cap Equity ETF
佔比1.09%
Pacer US Small Cap Cash Cows Growth Leaders ETF
佔比0.94%
Simplify Health Care ETF
佔比0.92%
Invesco S&P SmallCap Health Care ETF
佔比0.74%
VictoryShares Small Cap Free Cash Flow ETF
佔比0.7%
Royce Quant Small-Cap Quality Value ETF
佔比0.53%
Distillate Small/Mid Cash Flow ETF
佔比0.48%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
